• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Standard BioTools Inc.

    5/23/25 4:09:04 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $LAB alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001559779
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    STANDARD BIOTOOLS INC.
    SEC File Number
    001-34180
    Address of Issuer
    2 TOWER PLACE
    SUITE 2000
    SOUTH SAN FRANCISCO
    CALIFORNIA
    94080
    Phone
    6502666000
    Name of Person for Whose Account the Securities are To Be Sold
    Egholm Michael
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    54735151.7337982226805/23/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Class A05/22/2025Restricted Stock VestingIssuerCheckbox not checked547305/22/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Michael Egholm
    2 Tower Place
    Suite 2000
    South San Francisco � CA � 94080
    Common05/21/202547194866.70
    Michael Egholm
    2 Tower Place
    Suite 2000
    South San Francisco � CA � 94080
    Common05/22/202551165125.72

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    05/23/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Michael Egholm

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $LAB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LAB

    DatePrice TargetRatingAnalyst
    8/13/2025$1.55Buy → Hold
    TD Cowen
    2/27/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    4/16/2024$3.50Buy
    TD Cowen
    4/4/2024$3.25Buy
    Jefferies
    7/12/2023$4.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LAB
    SEC Filings

    View All

    Amendment: Standard BioTools Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    2/5/26 4:38:13 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    1/30/26 9:18:32 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

    1/8/26 7:10:25 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    12/4/25 8:59:44 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $10,053,280 worth of shares (7,700,000 units at $1.31) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/26/25 4:58:37 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $1,374,575 worth of shares (1,075,000 units at $1.28) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/20/25 7:45:54 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Casdin Partners Master Fund, L.P. bought $502,570 worth of shares (350,000 units at $1.44) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    12/4/25 8:59:44 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Casdin Partners Master Fund, L.P. bought $10,053,280 worth of shares (7,700,000 units at $1.31) (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/26/25 4:58:37 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President & CEO Egholm Michael covered exercise/tax liability with 63,529 shares, decreasing direct ownership by 1% to 5,617,837 units (SEC Form 4)

    4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

    11/24/25 5:05:15 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Standard BioTools Completes Sale of SomaLogic to Illumina

    Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy  Continuing Operations on track to achieve positive adjusted EBITDA in 2026 BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced it has completed the previously announced sale of SomaLogic to Illumina, Inc. (NASDAQ:ILMN) ("Illumina") for $350 million in upfront cash and up to $75 million in near-term earnout payments for aggreg

    1/30/26 9:09:00 AM ET
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

    BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) ("Standard BioTools" or the "Company") today announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56 million and revenue from continuing operations of approximately $24 million. For the full year 2025, the Company expects combined company revenue of approximately $185 million and revenue from continued operations of approximately $85 million. "Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and con

    1/8/26 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry

    Advancing next-generation IMC workflows with class-leading HCR imaging technologies for greater sensitivity and flexibility Molecular Instruments® (MI), the inventor of the HCR™ imaging platform, and Standard BioTools Inc. (NASDAQ:LAB) today announced a strategic collaboration to develop next-generation Imaging Mass Cytometry™ (IMC™) workflows powered by HCR imaging technologies, including the HCR HiFi Encoder for protein imaging with any primary antibody. The partnership combines HCR Gold for RNA and protein imaging with the Standard BioTools™ Hyperion™ Imaging System, extending the reach of IMC technology by introducing amplified detection for both RNA and protein for the first time.

    11/19/25 11:30:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Standard BioTools downgraded by TD Cowen with a new price target

    TD Cowen downgraded Standard BioTools from Buy to Hold and set a new price target of $1.55

    8/13/25 8:03:50 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools downgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets downgraded Standard BioTools from Overweight to Sector Weight

    2/27/25 6:22:46 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    TD Cowen initiated coverage on Standard BioTools with a new price target

    TD Cowen initiated coverage of Standard BioTools with a rating of Buy and set a new price target of $3.50

    4/16/24 8:09:43 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Financials

    Live finance-specific insights

    View All

    Standard BioTools Reports Second Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the second quarter ended June 30, 2025. Standard BioTools will no longer host its second quarter 2025 earnings call, previously scheduled for Monday, August 11 at 4:30 p.m. ET. Recent Highlights: Second quarter 2025 total combined company revenue of $42.0 million; Revenue from continuing operations of $21.8 millionAnnounced strategic sale of SomaLogic to Illumina for up to $425 million in total cash consideration plus future royalties, expected to close in the first half of 2026$240 million in cash & cash equivalen

    8/11/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025

    SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) today announced that it will report second quarter 2025 financial results on Monday, August 11, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investo

    7/21/25 7:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Reports First Quarter 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB) (the "Company" or "Standard BioTools") today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equivalents and no material debt as of March 31, 2025 "Standard BioTools delivered a solid first quarter in line with our expectations, reflecting focused execution in a

    5/6/25 4:01:00 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/14/24 3:32:10 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/12/24 6:01:47 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Standard BioTools Inc.

    SC 13G/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

    11/4/24 1:59:57 PM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $LAB
    Leadership Updates

    Live Leadership Updates

    View All

    Standard BioTools Appoints Alex Kim as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (NASDAQ:LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization. Michael Egholm, President and Chief Executive Officer of Standard BioTools, said, "I am thrilled to announce Alex as our next CFO. Having co-founded Standard BioTools with me, Alex's deep understan

    11/7/24 8:00:00 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Industry veteran Jeffrey Black brings 30 years of financial and operating leadership experience Vikram Jog to become Special Advisor for transition period SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – announced the appointment of Jeffrey Black as Senior Vice President and Chief Financial Officer effective today. Black will lead Standard BioTools' finance, accounting and investor relations functions, reporting to Michael Egholm, Ph.D., President and Chief Executive Officer. Vikram Jog will remain at the company for a period as Special Advisor to th

    5/15/23 7:30:14 AM ET
    $LAB
    Biotechnology: Laboratory Analytical Instruments
    Industrials